Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Company Information

Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, November 19, 2010 - Agennix AG (Frankfurt Stock 
Exchange: AGX) today announced that the Company will be presenting at
two investor conferences in November.

The Company will give a presentation at the upcoming German Equity 
Forum (Eigenkapitalforum) in Frankfurt, Germany. The German Equity 
Forum is an investor conference hosted by the Deutsche Boerse and KfW
SME Bank. The Company´s presentation is scheduled for Tuesday, 
November 23, 2010 at 12:45 CET at the Congress Center Messe 
Frankfurt.

Agennix will also give a presentation at the 22nd Annual Piper 
Jaffray Health Care Conference in New York, NY. The presentation is 
scheduled for Tuesday, November 30, 2010 at 8:30 AM ET/14:30 CET at 
The New York Palace Hotel. A live audio webcast will be available 
through the Agennix Web site at www.agennix.com. A replay will be 
available on the Web site following the live event.

About Agennix Agennix AG is a publicly listed biopharmaceutical 
company that is focused on the development of novel therapies that 
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company´s most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind, 
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III 
clinical trials in non-small cell lung cancer, and Agennix plans to 
develop this program further for the treatment of severe sepsis. 
Other clinical development programs include RGB-286638, a 
multi-targeted kinase inhibitor in Phase I testing and a topical gel 
form of talactoferrin for diabetic foot ulcers. Agennix´s registered 
seat is in Heidelberg, Germany. The Company has three sites of 
operation: Planegg/Munich, Germany; Princeton, New Jersey and 
Houston, Texas. For additional information, please visit the Agennix 
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to 
risks and uncertainties, many of which are beyond our control, that 
could cause future results, performance or achievements to differ 
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could 
differ materially depending on a number of factors, and we caution 
investors not to place undue reliance on the forward-looking 
statements contained in this press release. Forward-looking 
statements speak only as of the date on which they are made and 
Agennix undertakes no obligation to update these forward-looking 
statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

end of announcement                               euro adhoc

Further inquiry note:

For further information, please contact:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade